David A. Orlando

Case Western Reserve University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index12.5kcitations83works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinoids in leukemia and cellular processes(14), Click Chemistry and Applications(13), Genomics and Chromatin Dynamics(12), Protein Degradation and Inhibitors(12), Epigenetics and DNA Methylation(10)

Publications83 total

62The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
The Oncologist·2025Open Access
MICAL2 Is a Super Enhancer Associated Gene that Promotes Pancreatic Cancer Growth and Metastasis
2024· 1 citedOpen Access
The <i>SLC1A1</i> /EAAT3 Dicarboxylic Amino Acid Transporter is an Epigenetically Dysregulated Nutrient Carrier that Sustains Oncogenic Metabolic Programs
2023· 3 citedOpen Access
JoVE Video Dataset
2023
Alignment of Synchronized Time-Series Data Using the Characterizing Loss of Cell Cycle Synchrony Model for Cross-Experiment Comparisons
Journal of Visualized Experiments·2023· 1 cited
Supplementary Table S2: mRNA Cluster Signatures from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S3: Median Survival By Cluster from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S5 &amp; 6: GSEA of SY-1425 response from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S3: Median Survival By Cluster from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S7: GREAT analysis from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Figures from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S1: Sample mutations from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Methods and Figure Legends from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S5 &amp; 6: GSEA of SY-1425 response from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Data from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Data from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Methods and Figure Legends from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S2: mRNA Cluster Signatures from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Table S4: Enhancer, mRNA, and SY-1425 EC50 in AML cell lines from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
Supplementary Figures from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Richard A. Young(12), Christian Fritz(12), Jakob Lovén(9), Matthew G. Guenther(9), Steve Bilodeau(8), Steven B. Haase(8), Eric R. Olson(7), Shanhu Hu(7), Nisha Rajagopal(7), Siobhán M. Brady(6), Philip N. Benfey(6), Nan Rosemary Ke(6), Michael R. McKeown(6), Peter B. Rahl(5), Mei Wei Chen(5), Michael J. Bradley(5), Yixuan Ren(5), Emmanuelle di Tomaso(5), Matthew L. Eaton(5), Chris Fiore(5)